JOSEFIN PALMENJosefin has type 1 diabetes

and lives in Sweden

INTRODUCING NOVO NORDISK

02 03

NOVO NORDISK AT A GLANCE

WORKING WITHIN DIABETES, HAEMOPHILIA, GROWTH DISORDERS AND OBESITY

AFFILIATES IN77 COUNTRIES1

PRODUCTS MARKETED IN165 COUNTRIES1

28,000,000 PATIENTS USE OUR DIABETES CARE PRODUCTS1

R&D CENTRES IN CHINA, DENMARK, UK AND THE US2

EMPLOYS APPROXIMATELY41,400 PEOPLE1

In Novo Nordisk, we believe in change. We seek opportunities to contribute to healthier communities and better lives for all people. And we drive change by listening, learning and improving.

For more than 90 years we have been driving change to defeat diabetes and other serious chronic diseases, inspired by the courage of the people we support.

Every change in the right direction counts. From innovations in medicines and embarking on new global partnerships, to the everyday efforts and choices that people living with a chronic disease make, as they strive to live the life they want.

We work for a future where lives are not limited. To achieve this, we take the lead and continuously challenge the current situation by looking at change from new perspectives.

SUMITH KUMARSumith has type 1

diabetes and lives in India

DRIVING CHANGETO DEFEAT DIABETES AND OTHER SERIOUS CHRONIC DISEASES

“I now take greater care of my fitness and health in general, and I still love good food.”

HUW BEVANHuw has type 2 diabetes and lives in the UK

FOCUSED ON DIABETES

04 05

Novo Nordisk has been changing diabetes for more than 90 years. It is our heritage within diabetes that has given the experience and capabilities that also enable us to help people defeat other serious chronic diseases: haemophilia, growth disorders and obesity.

Diabetes poses one of today’s biggest global health challenges, affecting the lives of 415 million people worldwide.3 In nearly every country, the number of people with diabetes is increasing, and by 2040, it could rise to 642 million.3 Diabetes has also become a growing economic burden with healthcare systems struggling to match resources with increasing needs.3

1 IN 11 ADULTS HAVE DIABETES3

Novo Nordisk is a global leader within diabetes care. Our key contribution is to discover, develop and manufacture better biological medicines and make them accessible to people with diabetes throughout the world. We supply nearly half the insulin used worldwide and our global presence ensures access to treatment for the 28 million people who depend on it.1 Our ambition is to reach 40 million people with our diabetes care products by 2020 and to be at the forefront of new innovations. Producing life-saving medicines is a significant responsibility. However, to defeat diabetes we need to do more.

With our Changing Diabetes® commitment, we address the biggest unmet needs for people with diabetes. We work for a future where fewer people develop diabetes, everyone with diabetes is diagnosed earlier and everyone diagnosed receives adequate care and can live a life with as few limitations as possible. Globally, two-thirds of people with diabetes live in urban areas3, making cities an important focal point for tackling diabetes. Success is not something we can achieve on our own. Working together with patients, policymakers, healthcare professionals and non-governmental organisations we will continue to drive change where it is needed the most.

642 MILLIONREASONS TO MAKE A DIFFERENCE

06 07

642 MILLION PEOPLE GLOBALLY ARE ESTIMATED TO HAVE DIABETES BY 20403 1 IN 2 ADULTS WITH DIABETES DO NOT KNOW THEY HAVE IT3 DIABETES ACCOUNTED FOR 12% OF THE TOTAL SPEND ON HEALTHCARE WORLDWIDE IN 20153

4 OUT OF 5 PEOPLE WITH DIABETES LIVE IN LOW- AND MIDDLE-INCOME COUNTRIES3 2/3 OF PEOPLE WITH DIABETES LIVE IN CITIES3ONLY ABOUT HALF OF PEOPLE RECEIVING TREATMENT FOR DIABETES ACHIEVE THEIR TREATMENT TARGETS4

MEXICO CITYHome to nearly 9 million people and one of the first to take part in Cities Changing Diabetes. Read more about the programme on page 14

08

Our key contribution is to discover, develop and deliver better biological medicines, manufacture them to meet increasing global demand and make them accessible wherever they are needed. In Novo Nordisk we explore new research areas and continuously turn science and technologies into next generations of efficacious and safe biological medicines. In parallel, we design and develop innovative delivery devices based on patient insights.

Understanding what it is like to live with a serious chronic disease plays a key role in the development of new treatments. The company’s researchers are currently working on developing newer, more convenient insulins, including faster-acting and once-weekly long-acting insulins, to meet the needs of people living with diabetes.

We are striving to develop a cure for people with type 1 diabetes through our stem and beta cell research and are investigating a compound that conserves beta cell function and which may thereby prevent the progression of type 1 diabetes. Furthermore, we are researching longer-acting haemophilia treatments and new options for treating growth hormone disorders and obesity.

Moreover, we have established a new front in the fight against obesity by launching our first product for its treatment, and we are committed to further research and development in this area. Our world-class expertise in designing and developing innovative delivery devices is based on patient insights. Only by considering what is valuable from a patient perspective can we help people live a life with as few limitations as possible.

MEDICINE IS OUR KEY CONTRIBUTION

JOHAN PAULSSON AND KARIN HAMBORG ALBRECHTSEN

Principal scientist and principal technician Global Research in Denmark

HENNING HVID Specialist, Insulin

Pharmacology in Denmark

MARKET SHARE IN DIABETES127%

OF NOVO NORDISK’S GLOBAL WORK-FORCE20%

WORKS WITHIN R&D5

50 COUNTRIES WORLDWIDE1

CLINICAL TRIALS ARECONDUCTED IN MORE THAN

WORLD’S INSULIN1SUPPLIER OF NEARLY HALF OF THE

NOVO NORDISK INVESTS 13% OF SALES IN R&D1

Since Novo Nordisk was founded in 1923, we have developed our disease understanding and expertise in engineering, formulating, developing and delivering protein-based treatments, and efficient large-scale production of proteins, and today we are a world leader in diabetes care.

Diabetes is our largest therapeutic area and we have a broad portfolio of products, including rapid-acting, basal and fixed combination insulin, GLP-1, and combination insulin/GLP-1 products. We have a wide range of innovative durable and prefilled devices to make injections as simple, accurate and painless as possible. Furthermore, we are a pioneer in the research and development of oral GLP-1.

Novo Nordisk entered the haemophilia therapy market in 1996, using our expertise in recombinant protein development and manufacturing to meet a significant unmet medical need, with the only treatment option for the small community of people with haemophilia with inhibitors. Today, we have a range of products for haemophilia and rare bleeding disorders, one of the broadest clinical development programmes in haemophilia and a promising pipeline aimed at improving haemophilia treatment.

Novo Nordisk has been a pioneer in growth hormone therapy for over 40 years and was the first company to develop a liquid growth hormone in a pen device. Today, our growth hormone is the global market leader. Our goal is to provide the best treatment solution for children and adults who need growth hormone therapy and we are using our experience and knowledge in protein engineering to further research in this area.

Despite obesity reaching pandemic proportions, currently there are only a few pharmaceutical treatment options available. Novo Nordisk has been working in obesity research for more than 20 years. We entered this market in 2015 with the first once-daily GLP-1 analogue for the treatment of obesity. We are committed to addressing the significant unmet medical needs in obesity care and our ambition is to drive scientific progress in this disease area and develop new treatment options for obesity.

GLP-1 Molecule

DIABETES CARE OBESITYGROWTH DISORDERSHAEMOPHILIA

DEDICATED TO BREAKING NEW GROUND

10MICHAEL BATTAGLIA

Michael has a BMI of 35 and lives in the US

FLINN SARGEANT and mother Flinn has growth hormone disorder

and lives in the UK

YAQOUB AL QADERY Yaqoub has haemophilia A

and lives in Kuwait

RHONA BAPTISTERhona has type 2 diabetes

and lives in England

“If I could have one wish come true, it would be to never

have another bleed

CARL LYONS and mother

Carl has haemophilia A and lives in Denmark

13

IMPACT BEYOND MEDICINEProducing life-saving medicine is a significant responsibility: millions of people depend on us. However, to defeat serious chronic diseases, we need to do more than supply the right medicine. This is why we work in partnerships with patients, policymakers, healthcare professionals and non-governmental organisations to raise awareness, improve prevention, promote earlier diagnosis and expand access to care.

Information on some of the programmes, activities and initiatives we carry out to drive change can be found overleaf.

Our commitment to changing diabetes and changing haemophilia is reflected in a number of global and local initiatives

ACTIONS THAT DRIVE CHANGE

14 15

DAWN2™ and HERO studies

Novo Nordisk recognises the importance of addressing the psychosocial burden of living with a serious chronic disease. DAWN2 and HERO are international studies initiated to provide better understanding of this burden on people living with diabetes and haemophilia respectively.

Learn more at dawnstudy.com and herostudy.org

World Diabetes Day and World Haemophilia Day

Every year on World Diabetes Day on 14 November, and World Haemophilia Day on 17 April, Novo Nordisk together with international and local organisations unite communities to raise awareness of these chronic diseases.

Learn more at novonordisk.com/wdd and novonordisk.com/whd

The World Diabetes Foundation and Novo Nordisk Haemophilia Foundation

Novo Nordisk established the World Diabetes Foundation and Novo Nordisk Haemophilia Foundation with the aim of expanding access to diabetes and haemophilia care in less developed countries.

Learn more at worlddiabetesfoundation.org and nnhf.org

Team Novo Nordisk

Team Novo Nordisk is a global all-diabetes sports team of cyclists, triathletes and runners, spearheaded by the world’s first all-diabetes professional cycling team. Their mission is to inspire, educate and empower people affected by diabetes.

Learn more at teamnovonordisk.com

Cities Changing Diabetes

Cities Changing Diabetes is a partnership programme bringing together global and local partners with the aim of making ‘urban diabetes’ a healthcare priority and putting it on the agenda of those designing and managing cities for the future.

Learn more at citieschangingdiabetes.com

Changing Diabetes® in Children

Changing Diabetes® in Children is providing access to care including human insulin free of cost to 14,000 children with type 1 diabetes in low- and middle-income countries in Sub-Saharan Africa and South East Asia.

Learn more at novonordisk.com/cdic

Changing Diabetes® in Pregnancy

Managing diabetes in pregnancy offers an opportunity to reduce the risk of diabetes for both mother and child later in in life. This initiative works to increase access to testing for gestational diabetes (GDM), care and lifestyle education for pregnant women in low- and middle-income countries.

Learn more at novonordisk.com/cdip

Joint function

As part of our commitment to change haemophilia, our joint function programmes provide both education and support through Talking Joints® and guidance on the importance of fitness through the Novo Nordisk Haemophilia Fitness Camp.

Learn more at novonordisk.com/about-novo-nordisk/changing-haemophilia/Joint-function.html

Since Novo Nordisk was founded 90 years ago, we have been changing diabetes. Our key contribution is to discover and develop better biological medicines. However, to defeat this disease we need to do more, so we work to address the biggest unmet needs of people with diabetes.

Learn more at novonordisk.com/about-novo-nordisk

For more than three decades Novo Nordisk has been committed to changing haemophilia. As well as discovering and developing effective medicines, we work with our global partners to create better access to diagnosis and care with a focus on joint health.

Learn more at novonordisk.com/about-novo-nordisk

14 1716

FOCUSED, LONG-TERM THINKINGWe have built our business on the conviction that the formula for lasting success is to stay focused, think long-term and do business in a financially, socially and environmentally responsible way.

This conviction begins in the lab. It runs through clinical development and across the entire production and distribution chain until a product is in the hands of someone who needs it. And within the company, TakeAction and NovoHealth encourage

every employee to transform this conviction into real and immediate action.

Across borders and job functions we use our skills, dedication and ambition to help people defeat diabetes and other serious chronic diseases. At the same time we have the opportunity to work with extraordinary talent and benefit from a range of possibilities for professional and personal development. We call this a life-changing career.

A unique ownership structure

The Novo Nordisk Foundation is our main shareholder. The Foundation’s purpose is to provide a stable basis for the commercial and research activities of the Novo Group of companies, and to support scientific and humanitarian purposes. This unique ownership structure enables long-term planning and ensures that the company remains in Danish ownership.

TakeAction

TakeAction is our global employee volunteering programme. The programme gives employees the opportunity to bring our unique values to life by engaging in volunteer activities supporting social-, environmental- or health-related needs. From raising awareness about diabetes to supporting people with haemophilia in developing countries, to making a difference for the elderly or less privileged children, our employees are volunteering to change lives through TakeAction.

NovoHealth

Novo Nordisk believes that to prevent diseases such as type 2 diabetes and obesity, change must come from within. From a healthy lunch to the opportunity for exercise and a smoke-free workplace, NovoHealth encourages all employees to make healthy lifestyle choices every day.

The Novo Nordisk Way

Our values-based management system, the Novo Nordisk Way describes who we are, where we want to go and how we work. It underpins all decisions we make and supports a long-term, patient-focused business approach.

Socially responsible

Environmentallyresponsible

Financially responsible

17

The Triple Bottom Line

To ensure that we can be in business for the next generations, we must always act responsibly, considering the impacts of our business on people, communities and the environment when we make decisions. We call this approach the Triple Bottom Line.

REFERENCES

1. Novo Nordisk Annual Report 2016. Available at novonordisk.com. Accessed February 2017.

2. novonordisk.com. About R&D. Available at novonordisk.com/rnd/about-rd.html. Accessed February 2016.

3. International Diabetes Federation. IDF Diabetes Atlas, seventh edition, 2015. Available at idf.org/diabetesatlas. Accessed February 2017.

4. Hart JT. Rule of Halves: implications of increasing diagnosis and reducing dropout for future workload and prescribing costs in primary care. British Journal of General Practitioners 1992; 42(356):116–119, and Smith WCS, Lee AJ, Crombie IK, Tunstall-Pedoe H. Control of blood pressure in Scotland: the rule of halves. British Medical Journal 1990; 300:981–983.

5. novonordisk.com. Facts and Figures. Available at novonordisk.com/about-novo-nordisk/novo-nordisk-in-brief/facts-and-figures.html. Accessed March 2015.

6. World Health Organization. Fact File 2. Available at who.int/features/factfiles/ obesity/facts/en/index1.html. Accessed November 2013.

7. HERO study. Available at herostudy.org/hero-insights/burden. Accessed June 2015.

1918

ZANDILE SIGNORIA MZAYIFANIZandile has type 2 diabetes

and lives in South Africa

WE ARE NOT DONE CHANGING LIVESWe have come a long way since the first patients were treated with Novo Nordisk insulin in 1923, but there are still challenges ahead. Rates of obesity and type 2 diabetes are rising in most countries3,6 and many people with haemophilia face anxiety and physical pain on a daily basis7. Inspired by their courage and guided by the Novo Nordisk Way, we will continue to do everything we can to drive meaningful, positive change in their lives.

Corporate Branding, D

enmark, February 2016 . The A

pis bull logo is a registered trademark of N

ovo Nordisk A

/S

Novo Nordisk A/SNovo Allé2880 BagsværdDenmarkTel +45 4444 8888CVR number 24 25 67 90novonordisk.com

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic diseases: haemophilia, growth disorders and obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in 77 countries and markets its products in 165 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com

Follow us